Dual PARP-1/CK2α Inhibitors Aim Beyond HRD-Restricted Tumors
- Researchers designed a new class of small molecules built on a benzothieno[3,2-d]pyrimidin-4(1H)-one scaffold that simultaneously inhibits PARP-1 and casein kinase 2 alpha (CK2α).
- PARP-1 inhibitors typically benefit only tumors with homologous recombination deficiency (HRD); pairing PARP-1 blockade with CK2α inhibition, a kinase linked to DNA damage response and cell survival signaling, is proposed to extend efficacy to HRD-proficient tumors and limit metastatic spread.
- Structure-activity relationship exploration identified substituents on the tricyclic core that support potent, balanced binding at both targets.
- In cellular and tumor models, the dual inhibitors reportedly show antiproliferative and anti-metastatic activity independent of HRD status, supporting dual-target inhibition as a route beyond BRCA-mutant-restricted use.
Holding balanced dual-target SAR on one scaffold is the real difficulty here, not the headline claim — PARP-1's nicotinamide pocket and CK2α's ATP site are shaped nothing alike, so a substituent you add to hold potency at one target can quietly tank the other. I'd want the full SAR table, not just the lead actives, before believing that balance survives further optimization. The real payoff isn't PARP-1 potency itself, it's escaping the BRCA/HRD ceiling — another single-target PARP inhibitor chasing olaparib's lane is a hard sell, but HRD-independent activity actually opens new patient populations. The tricyclic benzothienopyrimidinone core gives usable vectors for dual substitution, though fusing two pharmacophores tends to inflate MW and logP fast. Next data I need: kinome-wide selectivity beyond CK2α, in vivo therapeutic window, and whether the anti-metastatic signal holds up against a PARP-1-only comparator.